Clinical Trials Logo

Clinical Trial Summary

The objective of this study is to evaluate the pharmacodynamic (PD) bioequivalence (BE) of albuterol inhalers, test formulation: Albuterol Sulfate HFA inhalation aerosol 108 mcg (equal to albuterol base 90 mcg) per actuation and reference formulation: ProAir HFA (albuterol sulfate) or FDA authorized generic: Albuterol Sulfate HFA (Teva Pharmaceutical USA, Inc.) Inhalation Aerosol 108 mcg (equal to albuterol base 90 mcg) per actuation manufactured by two different manufacturers using methacholine bronchoprovocation challenge test in patients with stable mild asthma.


Clinical Trial Description

This study will be conducted using the single-dose, randomized, double-blind, double-dummy, four-sequence, four-treatment, and multiple-center study design to evaluate the PD bioequivalence between the test albuterol sulfate (T) inhalation aerosol 108 mcg per actuation (eq. to albuterol base 90 mcg/puff) and the reference albuterol sulfate (R) (ProAir HFA or FDA authorized generic: Albuterol Sulfate HFA [Teva Pharmaceutical USA, Inc.]) inhalation aerosol 108 mcg per actuation (equal to albuterol base 90 mcg/puff). The two products will be studied using a crossover design in patients with stable mild asthma by administering a minimum of 3 doses of reference product (0, 90, 180 mcg albuterol) and 2 doses of test product (0, 90 mcg albuterol). The bronchodilation potency of albuterol sulfate are measured by the inhibition effects of methacholine challenge on the bronchodilation, as indicated by increase in the provocative concentration of methacholine required to produce a 20% decrease in FEV1 (PC20). ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04912596
Study type Interventional
Source Intech Biopharm Ltd.
Contact Jasmine Kuo
Phone +886-2-7721-8877
Email jasmine.i199@intechbiopharm.com
Status Recruiting
Phase N/A
Start date August 15, 2022
Completion date April 2024

See also
  Status Clinical Trial Phase
Completed NCT00380354 - Study To Evaluate GSK256066 In Subjects With Mild Bronchial Asthma Phase 2
Completed NCT00453778 - A Study To Investigate The Effect Of Inhaled Fluticasone Propionate On The Bronchial Responsiveness To Leukotriene D4 In Asthmatics Patients Phase 4
Recruiting NCT04796844 - MANI Real-life Perspective Observatory
Completed NCT00466596 - Effect of House Dust Mite Allergen Challenge in Persons Using 1200 mg Gamma Tocopherol Supplements Phase 1
Not yet recruiting NCT06433921 - A Study to Compare the Relative Potency of Salbutamol Administered Via Metered Dose Inhalers (MDI) Containing Propellants HFA-152a to HFA-134a in Mild Asthmatics Aged 18 to 65 Inclusive Phase 1
Not yet recruiting NCT06411886 - Measurements of Inflammation Induced by Allergen Inhalation Challenge in Mild Allergic Asthma N/A
Completed NCT00287365 - Genetic Susceptibility to Ozone in Mild Asthmatic Volunteers N/A
Completed NCT02892344 - Study of QMF149 (150/80 µg) Compared With MF Twisthaler® (200 µg) in Patients With Asthma Phase 3
Completed NCT00448851 - Study of Dust Mite Inhalation in Humans Phase 1
Completed NCT03838731 - Study in Cat-Allergic Patients With Asthma to Evaluate the Efficacy of a Single Dose of REGN1908-1909 to Reduce Bronchoconstriction Upon Cat Allergen Challenge Phase 2
Completed NCT03421730 - A Study of the Pharmacokinetics, Safety and Tolerability of Single Doses of VR647 Inhalation Suspension Administered Using the VR647 Inhalation System in Children With Wheezing, Reactive Airway Disease or Mild Asthma Phase 1